Nasdaq · Biotech stocks database

ORMP — Oramed Pharmaceuticals Inc.

ORMP (Oramed Pharmaceuticals Inc.) stock: $4.74, $197.2M market cap, $16.1M cash, $181.1M EV, $197.2M fully diluted market cap. Next expected readout: Apr-27. Lead program: ORMD-0801 8 mg (Type 2 Diabetes Mellitus), Phase 3. Data from Fully Diluted's biotech stocks database.

Share price

$4.74

Market cap

$197.2M

Cash

$16.1M

Enterprise value

$181.1M

Balance sheet

Cash	$16.1M
Debt	$0.0M
Net cash	$16.1M
Enterprise value	$181.1M
Basic shares	41.3M shares
Fully diluted shares	41.6M shares
Fully diluted market cap	$197.2M
Cash per share	$0.39

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading ORMP daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Jun 6 - Jul 18	ORMD-0801 8 mg	Phase 3	Type 2 Diabetes Mellitus	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Lead drug	ORMD-0801 8 mg
Lead indication	Type 2 Diabetes Mellitus
Lead phase	Phase 3
Active trials	1

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT06731075	Phase 3	Not yet recruiting	Sponsor	Oramed, Ltd.	—	Type 2 Diabetes Mellitus	—

Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 1 active trials for Oramed, Ltd. on ClinicalTrials.gov

Get the weekly biotech catalyst rundown.
Cash runways, financings, and trial readouts for all 714 stocks.

Subscribe to Compounding Ego

ORMP — Oramed Pharmaceuticals Inc.

Balance sheet

Price history

Upcoming catalysts

Pipeline

Active clinical trials